SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health Inc (HIMS) is a top trending stock following its earnings release, which presented mixed results and cautious near-term guidance, amplified by ongoing legal and regulatory pressures including a lawsuit from Novo Nordisk and investigations by the FDA, DOJ, and SEC. While some in the community view the stock as oversold, highlighting its share buyback program and long-term growth, many express significant bearish sentiment due to these legal headwinds and concerns over declining gross margins.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending amid intense speculation around its bid for Warner Bros. Discovery, as Paramount reportedly submits a higher offer, leading to widespread community debate on whether the streaming giant should raise its price or walk away to avoid further stock depreciation and navigate increasing regulatory and political scrutiny.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is trending sharply lower after an Anthropic blog post highlighted Claude AI's capabilities in COBOL modernization, sparking market fears about AI disruption to legacy services; however, many in the community view the sell-off as an overreaction, citing IBM's existing AI integrations and comprehensive enterprise solutions.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is experiencing intense community discussion ahead of its imminent earnings report, with analysts widely expecting strong results driven by insatiable AI infrastructure demand. However, despite broad bullish sentiment around its continued AI dominance, significant skepticism persists regarding whether the stock can maintain its momentum post-earnings, with many anticipating a "sell the news" event.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR Protocol is trending as its NEAR Intents technology drives significant cross-chain activity and integration with major ecosystems, alongside strong community discussion around its AI-native capabilities. Growing user adoption and institutional interest, including a Grayscale Trust filing, are fueling optimism for its future performance.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is gaining significant attention following its public debut on the NYSE and recent institutional interest, sparking community debate over its innovative neutral-atom quantum technology and existing commercial applications in contrast to peers, amidst discussions of typical post-SPAC market dynamics.

Seeker is building a decentralized mobile ecosystem designed to challenge entrenched mobile incumbents through its TEEPin network architecture and community governance. It aims to solve the pain points of centralized app store gatekeeping, lack of developer freedom, and restricted user access to crypto applications. The vision is to create a community-owned platform with decentralized governance, no gatekeepers, direct developer-user access, and TEEPin security architecture.

Saakuru

The Seeker Solana Smartphone Token, SKR, is experiencing substantial upside following recent exchange listings and a special offer providing a 50% discount on the Seeker phone when purchased with SKR, sparking community debate over its "Bonk 2.0" potential versus pump-and-dump risks amidst reports of significant airdrops to holders.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Johnson & Johnson is trending due to reports of a potential major sale of its orthopedics unit, signaling a strategic pivot and fueling community discussion on its impact on future growth. Simultaneously, escalating talc litigation with recent significant jury awards has sparked intense debate regarding its financial outlook as it pursues new drug approvals and cell therapy investments.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is trending due to recent bullish analyst price target revisions and substantial institutional buying, with the community emphasizing its undervalued position and crucial role in providing advanced optical interconnects and custom AI chips for major cloud providers.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is a top trend as its weight-loss drug demonstrated superior efficacy over a competitor's in a head-to-head trial, complemented by a strong earnings report and bullish outlook that reinforce its best-in-class standing in the pharmaceutical market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Citius Pharmaceuticals Q1 Earnings Report: What Investors Need to Know

Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR

Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of...

Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR

Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR PR Newswire...

Citius Oncology Expands International Distribution of LYMPHIR to European Union Through Exclusive Agreement with Uniphar

Citius Oncology Expands International Distribution of LYMPHIR to European Union Through Exclusive Agreement with Uniphar Citius Oncology Expands International Distribution of LYMPHIR to European...

Citius Pharmaceuticals (CTXR) Surges 22% After Hours Here's Why

Citius Pharmaceuticals shares jumped 22.12% after hours following the commercial launch of its LYMPHIR therapy and a fiscal 2025 business update.read more...

Citius Pharmaceuticals Inc. Full Year Loss Decreases

(RTTNews) - Citius Pharmaceuticals Inc. (CTXR.OB) released Loss for full year of -$37.43 million...

Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update PR Newswire...

Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business...

Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules Citius Oncology Announces Closing of $18 Million...

Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules Citius Oncology Announces $18 Million Concurrent Registered...

Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. The company was founded by Ralph Montrone, Leonard Mazur, Myron Holubiak on January 23, 2007 and is headquartered in Cranford, NJ.

CTXR
Citius Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CTXR News

CTXRCitius Pharmaceuticals Inc